Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2025)

Protagonist Therapeutics' Current Deferred Revenue history spans 9 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 49.45% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $9.5 million, down 49.45%, while the annual FY2025 figure was $9.5 million, 49.45% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $9.5 million at Protagonist Therapeutics, down from $14.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $20.1 million in Q2 2024 and bottomed at $3000.0 in Q3 2023.
  • The 5-year median for Current Deferred Revenue is $2.2 million (2021), against an average of $7.4 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 98.57% in 2022 before it soared 656433.33% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.6 million in 2021, then plummeted by 95.69% to $69000.0 in 2022, then plummeted by 95.65% to $3000.0 in 2023, then skyrocketed by 629600.0% to $18.9 million in 2024, then tumbled by 49.45% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Current Deferred Revenue are $9.5 million (Q4 2025), $14.2 million (Q3 2025), and $14.7 million (Q2 2025).